Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GPR6 | P46095 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3638771 | 0.89 | KMT2A (0.36) | MEN1KMT2AGPR6MAPT | |
| SCHEMBL12420246 | 0.89 | ALB (0.42) | ALBPKMCYP2C9 | |
| SCHEMBL4393229 | 0.84 | MEN1 (0.39) | MEN1KMT2AGPR6LMNA | |
| SCHEMBL4379436 | 0.82 | MEN1 (0.43) | MEN1KMT2AGPR6AKR1C3SCN9A | |
| SCHEMBL4382730 | 0.80 | MEN1 (0.42) | MEN1KMT2AGPR6AKR1C3CYP2C9 | |
| SCHEMBL8223748 | 0.80 | GPR6 (0.38) | MEN1KMT2AGPR6AKR1C3SCN9A | |
| SCHEMBL4379541 | 0.79 | MEN1 (0.41) | MEN1KMT2AGPR6AKR1C3MAPT | |
| SCHEMBL4382938 | 0.79 | MEN1 (0.41) | MEN1KMT2AGPR6AKR1C3SCN9A | |
| SCHEMBL4395257 | 0.78 | CYP11B1 (0.43) | MEN1KMT2AGPR6AKR1C3LMNA | |
| SCHEMBL4386294 | 0.78 | MEN1 (0.40) | MEN1KMT2AGPR6AKR1C3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| EP-2164326-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | Euro-Celtique, S.A. (LU) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | CACNA1E, CACNA1B, CACNA1S | MEN1 3484/4885KMT2A 2564/4885GPR6 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.